LFST Lifestance Health Group Inc

LifeStance Health Group Director Robert Bessler recently sold 119,942 shares of the company's stock for over $844,000, reducing his stake by 8.34%. This sale is part of multiple transactions in December totaling around 220,086 shares sold for approximately $1.55 million. The company (NASDAQ:LFST) is trading near $7.06 with a market cap of $2.75 billion, receiving a "Moderate Buy" consensus rating from analysts despite remaining slightly unprofitable.

LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of the company's stock for a total of $11,975.04 on December 22nd, reducing his position by 0.13%. This sale is part of a series of transactions by Bessler from December 12th to 22nd, totaling approximately 220,086 shares for about $1.55 million, though he still retains 1,318,133 shares valued at around $9.28 million. LifeStance Health Group's stock traded at $7.06, with a market capitalization of $2.75 billion, and the company recently surpassed quarterly EPS and revenue estimates while maintaining a "Moderate Buy" consensus rating from analysts with an $8.83 target.

Robert Bessler, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), sold a total of $856,366 worth of common stock across several transactions on December 19 and 22, 2025. These sales were executed at a price of $7.04 per share, with shares sold both directly and indirectly through LLCs. Following these transactions, Bessler still indirectly holds over 2.7 million shares in the company.

BTIG analyst David Larsen reiterated a bullish stance on LifeStance Health Group (LFST), raising the price target from $9 to $10, forecasting a 42% upside potential for investors. This positive outlook is driven by anticipated strong medical utilization trends in 2026, stemming from a favorable labor market and increased demand for medical oncology, mental health services, and specialty medications. Currently, all seven analysts covering LFST have issued Buy ratings, with a consensus 1-year average price target of $9, suggesting a 27.7% upside.

Ann Varanakis, Chief People Officer at LifeStance Health Group Inc (LFST), sold 50,000 shares of the company on December 17, 2025. This transaction increased her total shares owned to 315,610. The stock, currently trading at $6.9, is considered modestly undervalued with a GuruFocus Value of $8.14.

An independent director at LifeStance Health Group (NASDAQ:LFST) recently sold approximately US$645k worth of shares, representing a 3.1% reduction in their holding. This was the largest insider sale in the past year, and while the sale occurred near the current share price, it indicates more selling than buying activity from insiders over the last year. Despite insiders owning a significant 7.8% of the company, the analysis suggests caution regarding the stock due to the recent selling trend.